Reata Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops novel therapeutics for patients with serious or life-threatening diseases by targeting molecular pathways that regulate cellular metabolism and inflammation.
Adequate balance sheet with limited growth.
Share Price & News
How has Reata Pharmaceuticals's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: RETA's share price has been volatile over the past 3 months.
7 Day Return
1 Year Return
Return vs Industry: RETA exceeded the US Pharmaceuticals industry which returned -7% over the past year.
Return vs Market: RETA exceeded the US Market which returned -14.9% over the past year.
Price Volatility Vs. Market
How volatile is Reata Pharmaceuticals's share price compared to the market and industry in the last 5 years?
Simply Wall St News
1 week ago | Simply Wall StRead This Before Buying Reata Pharmaceuticals, Inc. (NASDAQ:RETA) Shares
2 months ago | Simply Wall StOur Take On Reata Pharmaceuticals, Inc.'s (NASDAQ:RETA) CEO Salary
3 months ago | Simply Wall StCan We See Significant Insider Ownership On The Reata Pharmaceuticals, Inc. (NASDAQ:RETA) Share Register?
Is Reata Pharmaceuticals undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate RETA's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate RETA's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: RETA is unprofitable, so we can't compare its PE Ratio to the Pharmaceuticals industry average.
PE vs Market: RETA is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate RETA's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: RETA is overvalued based on its PB Ratio (17.5x) compared to the US Pharmaceuticals industry average (2.4x).
How is Reata Pharmaceuticals forecast to perform in the next 1 to 3 years based on estimates from 6 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: RETA is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: RETA is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: RETA is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: RETA's revenue (62.9% per year) is forecast to grow faster than the US market (7.1% per year).
High Growth Revenue: RETA's revenue (62.9% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if RETA's Return on Equity is forecast to be high in 3 years time
How has Reata Pharmaceuticals performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: RETA is currently unprofitable.
Growing Profit Margin: RETA is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: RETA is unprofitable, and losses have increased over the past 5 years at a rate of -74.5% per year.
Accelerating Growth: Unable to compare RETA's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: RETA is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (-0.2%).
Return on Equity
High ROE: RETA has a negative Return on Equity (-112.97%), as it is currently unprofitable.
How is Reata Pharmaceuticals's financial position?
Financial Position Analysis
Short Term Liabilities: RETA's short term assets ($669.3M) exceed its short term liabilities ($192.0M).
Long Term Liabilities: RETA's short term assets ($669.3M) exceed its long term liabilities ($233.5M).
Debt to Equity History and Analysis
Debt Level: RETA's debt to equity ratio (60.4%) is considered high.
Reducing Debt: Insufficient data to determine if RETA's debt to equity ratio has reduced over the past 5 years.
Inventory Level: RETA has a low level of unsold assets or inventory.
Debt Coverage by Assets: RETA's debt is covered by short term assets (assets are 4.3x debt).
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: RETA has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: RETA has sufficient cash runway for 1.7 years if free cash flow continues to reduce at historical rates of -23.8% each year.
What is Reata Pharmaceuticals's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate RETA's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.
High Dividend: Unable to evaluate RETA's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if RETA's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if RETA's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of RETA's dividend in 3 years as they are not forecast to pay a notable one for the US market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
J. Huff (65yo)
Mr. J. Warren Huff has been the Chief Executive Officer and President of Reata Pharmaceuticals, Inc. (formerly, Reata Discovery Inc) since founding in 2002 and has been its Chairman since 2002. Mr. Huff is ...
CEO Compensation Analysis
Compensation vs Market: J.'s total compensation ($USD934.50K) is below average for companies of similar size in the US market ($USD5.63M).
Compensation vs Earnings: J.'s compensation has been consistent with company performance over the past year.
|Chief Medical Officer & Executive VP of Product Development||no data||US$625.50k||0.47% $21.2m|
|CFO & Executive VP||0.67yr||no data||no data|
|Executive Vice President of Operations||0.67yr||US$427.50k||0.079% $3.5m|
|VP & Chief Accounting Officer||no data||no data||0.046% $2.1m|
|Executive VP & Chief Legal Officer||5yrs||no data||no data|
|VP of Corporate Communications & Strategy||no data||no data||no data|
|Vice President of Marketing||1.83yrs||no data||no data|
|VP & Chief Human Resources Officer||1yr||no data||no data|
|Chief Development Officer & Senior VP of Regulatory||no data||no data||no data|
Experienced Management: RETA's management team is not considered experienced ( 1.4 years average tenure), which suggests a new team.
|Independent Director||4.17yrs||US$263.81k||9.56% $429.8m|
|Lead Independent Director||no data||US$298.93k||0.0054% $241.1k|
|Independent Director||15.33yrs||US$260.79k||1.09% $49.1m|
|Independent Director||15.75yrs||US$267.92k||0.30% $13.4m|
|Independent Director||3.08yrs||US$292.93k||no data|
Experienced Board: RETA's board of directors are seasoned and experienced ( 15.3 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 9.8%.
Reata Pharmaceuticals, Inc.'s company bio, employee growth, exchange listings and data sources
- Name: Reata Pharmaceuticals, Inc.
- Ticker: RETA
- Exchange: NasdaqGM
- Founded: 2002
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$4.498b
- Shares outstanding: 33.23m
- Website: https://www.reatapharma.com
Number of Employees
- Reata Pharmaceuticals, Inc.
- 5320 Legacy Drive
- United States
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|RETA||NasdaqGM (Nasdaq Global Market)||Yes||Class A Common Stock||US||USD||May 2016|
|2R3||DB (Deutsche Boerse AG)||Yes||Class A Common Stock||DE||EUR||May 2016|
Reata Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops novel therapeutics for patients with serious or life-threatening diseases by targeting molecular pathways that regulate cellular metabolism and inflammation. The company is developing Phase III clinical trial programs, including bardoxolone methyl (bardoxolone) for the treatment of patients with chronic kidney disease(CKD) caused by Alport syndrome, as well as for a form of pulmonary arterial hypertension associated with connective tissue disease; omaveloxolone that is Phase II clinical trial to treat Friedreich’s ataxia; and conduct phase 2 study for various form of CKD, such as IgA nephropathy, type 1 diabetic, and focal segmental glomerulosclerosis. It is also developing RTA 901, which completed Phase 1 clinical trials for the treatment of neurological diseases, such as diabetic neuropathy; and RORgT Inhibitors that are in the preclinical development phase for the potential treatment of a range of autoimmune, inflammatory, and fibrotic diseases. In addition, the company offers bardoxolone for the treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD), as well as initiated phase 3 Falcon trial for the treatment of ADPKD. Further, it has a strategic collaboration agreement with Kyowa Kirin Co., Ltd. to develop and commercialize bardoxolone for renal, cardiovascular, diabetes, and various other related metabolic indications in Japan, China, Hong Kong, Macao, South Korea, Taiwan, Thailand, Singapore, the Philippines, Malaysia, Indonesia, Brunei, Vietnam, Laos, Myanmar, and Cambodia; and AbbVie Inc. to jointly research, develop, and commercialize all second- and later-generation Nrf2 activators for all indications other than renal, cardiovascular, and metabolic indications. The company was formerly known as Reata Discovery, Inc. and changed its name to Reata Pharmaceuticals, Inc. in May 2005. Reata Pharmaceuticals, Inc. was founded in 2002 and is headquartered in Plano, Texas.
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/04/03 09:00|
|End of Day Share Price||2020/04/02 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.